Sailong Pharmaceutical Group Co.Ltd(002898) ( Sailong Pharmaceutical Group Co.Ltd(002898) ) disclosed the 2021 annual report on April 26. During the reporting period, the company achieved an operating revenue of 247 million yuan, a year-on-year increase of 104.73%; The net profit attributable to the shareholders of the listed company was a loss of 233414 million yuan, a significant year-on-year reduction. As of December 31, 2021, the total assets of the company were 883 million yuan, and the owner’s equity attributable to the shareholders of the listed company was 564 million yuan.
The annual report shows that the company has further increased investment in product R & D, and gradually entered the variety harvest period after more than ten years of layout and accumulation. At present, 8 varieties of tegacyclin for injection have passed the evaluation of the efficacy and quality consistency of generic drugs; The over evaluated product specifications of milrinone injection 10ml: 10mg, parecoxib sodium for injection 20mg and tranexamic acid injection 5ml: 0.5g were added. Many products of the company have passed the evaluation of generic drug efficacy and quality consistency and added specifications, which is conducive to optimizing the product structure of the company, better meeting the needs of clinical medication, and further improving the market competitiveness of products.
During the reporting period, the company established 26 generic raw materials and preparations projects, and completed the research and application of class II or III medical devices such as recombinant human collagen functional dressing, medical wound dressing and medical skin repair. Up to now, the third class new drug levopoprazole sodium has been declared for production, and the second class new drug right lansoprazole has completed phase II clinical and will carry out phase III clinical soon. The company’s product layout has been continuously enriched, and the variety structure has been further optimized.
In terms of marketing, the sales layout of new products has achieved remarkable results. Argatroban injection and tranexamic acid injection have won the exclusive bid for “eight provinces and two districts” centralized drug procurement, ornithine aspartate injection has won the exclusive bid for Lujin inter provincial alliance centralized collection, and tegacyclin for injection has won the exclusive bid for Fujian provincial centralized collection. The market share of products has gradually increased.
